论文部分内容阅读
方法:用1ml生理盐水溶解尿激酶1万单位,半球后注射尿激酶5000单位,每周1次,10次为1个疗程。本文10例中,男6例9眼,女4例5眼。年龄最大者65岁,最小23岁。引起玻璃体出血原因,眼球挫伤性2例2眼,视网膜血管炎性1例1眼,白内障术后1例1眼,视网膜动脉硬化2例2眼,静脉周围炎2例4眼,糖尿病2例4眼。病程最长3年,最短15天。疗效标准:显效即视力增进5行以上或光感手动增进≥0.2,有效即视力增进2～5行或光感手动增进<0.2,视力无变化为无效。
Methods: Dissolve 10,000 units of urokinase in 1 ml of normal saline and 5000 units of urokinase in the hemisphere once a week for 10 times as a course of treatment. This article 10 cases, 6 males and 9 females, 4 females 5 eyes. The oldest is 65 years old and the youngest is 23 years old. Causes of vitreous hemorrhage, eyeball contusion in 2 cases 2 eyes, 1 case of retinal vasculitis in 1 case, 1 case of cataract surgery in 1 case, 2 cases of retinal atherosclerosis in 2 cases, 4 cases of venous inflammation in 2 cases, 2 cases of diabetes mellitus 4 eye. Duration of up to 3 years, the shortest 15 days. Efficacy standards: markedly improved visual acuity of more than 5 lines or light sense of manual increase ≥0.2, effective that visual acuity improved 2 to 5 lines or light sense of manual increase <0.2, no change in vision invalid.